CND Life Sciences Secures Financing for Growing Syn-One Test® and Neurology Mission#United_States#Scottsdale#CND_Life_Sciences#Syn-One_Test#S-Curve_Partners
CND Life Sciences Secures Financing for Growing Syn-One Test® and Neurology Mission
CND Life Sciences announced significant financing to enhance its Syn-One Test® platform and drive advancements in precision neurology diagnostics.
third-news.com
August 4, 2026 at 12:36 PM
CND Life Sciences Secures Financing for Growing Syn-One Test® and Neurology Mission#United_States#Scottsdale#CND_Life_Sciences#Syn-One_Test#S-Curve_Partners
CND Life Sciences Marks a Milestone with 50,000th Syn-One Test® Using Skin Biopsy Technology#USA#Scottsdale#CND_Life_Sciences#Syn-One_Test#Neurodiagnostics
CND Life Sciences Marks a Milestone with 50,000th Syn-One Test® Using Skin Biopsy Technology
CND Life Sciences celebrates the completion of its 50,000th Syn-One Test, a breakthrough in diagnosing synucleinopathies, enhancing patient care nationwide.
third-news.com
November 6, 2025 at 1:14 PM
CND Life Sciences Marks a Milestone with 50,000th Syn-One Test® Using Skin Biopsy Technology#USA#Scottsdale#CND_Life_Sciences#Syn-One_Test#Neurodiagnostics
CND Life Sciences Achieves FDA Breakthrough Device Designation for Syn-One Test®#USA#Scottsdale#CND_Life_Sciences#Syn-One_Test#FDA_Breakthrough
CND Life Sciences Achieves FDA Breakthrough Device Designation for Syn-One Test®
CND Life Sciences has received the FDA's Breakthrough Device Designation for its Syn-One Test, aiding in the diagnosis of synucleinopathies in patients.
third-news.com
October 7, 2025 at 6:17 PM
CND Life Sciences Achieves FDA Breakthrough Device Designation for Syn-One Test®#USA#Scottsdale#CND_Life_Sciences#Syn-One_Test#FDA_Breakthrough
CND Life Sciences' Innovative Syn-One Test: A Breakthrough for REM Sleep Behavior Disorder Diagnosis#United_States#Scottsdale#CND_Life_Sciences#Syn-One_Test#Alpha-Synuclein
CND Life Sciences' Innovative Syn-One Test: A Breakthrough for REM Sleep Behavior Disorder Diagnosis
CND Life Sciences unveiled promising results from their Syn-One Test, detecting alpha-synuclein in skin biopsies of patients with REM sleep behavior disorder, highlighting its potential as a diagnostic tool.
third-news.com
June 5, 2025 at 2:06 PM
CND Life Sciences' Innovative Syn-One Test: A Breakthrough for REM Sleep Behavior Disorder Diagnosis#United_States#Scottsdale#CND_Life_Sciences#Syn-One_Test#Alpha-Synuclein
CND Life Sciences Secures $13.5M Series A Funding for Neurodiagnostic Innovations#United_States#Scottsdale#CND_Life_Sciences#Syn-One_Test#Neurodiagnostics
CND Life Sciences Secures $13.5M Series A Funding for Neurodiagnostic Innovations
CND Life Sciences announces successful $13.5 million Series A equity round, aiming to enhance neurodiagnostics and patient care.
third-news.com
May 1, 2025 at 3:08 PM
CND Life Sciences Secures $13.5M Series A Funding for Neurodiagnostic Innovations#United_States#Scottsdale#CND_Life_Sciences#Syn-One_Test#Neurodiagnostics
CND Life Sciences Reveals Groundbreaking Test for Neurodegenerative Disease Diagnosis#USA#Scottsdale#Neurodegenerative_Diseases#CND_Life_Sciences#Syn-One_Test
CND Life Sciences Reveals Groundbreaking Test for Neurodegenerative Disease Diagnosis
CND Life Sciences published a study demonstrating the Syn-One Test's effectiveness in diagnosing neurodegenerative diseases accurately.
third-news.com
December 18, 2024 at 4:03 PM
CND Life Sciences Reveals Groundbreaking Test for Neurodegenerative Disease Diagnosis#USA#Scottsdale#Neurodegenerative_Diseases#CND_Life_Sciences#Syn-One_Test